Drugs / Dendritic Cell
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01677962 | Aug 2012 → Sep 2014 | pancreatic adenocarcinoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02638857 | Sep 2015 → Mar 2017 | hepatocellular carcinoma | Second Military Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02632019 | Sep 2015 → Mar 2017 | biliary tract cancer | Second Military Medical University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00365872 | May 2006 → Jun 2012 | soft tissue sarcoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05955157 | Jan 2023 → Dec 2024 | pancreatic ductal adenocarcinoma | University of Malaya | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02638857 ↗ |
| Modality | Cell therapy | “injection of the patient's own immune related white blood cells into their tumor” NCT00365872 ↗ |
| Route | Other | “DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.” NCT00365872 ↗ |